Current Liabilities
Other Commercial Liabilities
Amgen Other Commercial Liabilities decreased by 10.5% to $16.58B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 3.8%, from $17.23B to $16.58B. Over 5 years (FY 2020 to FY 2025), Other Commercial Liabilities shows an upward trend with a 12.8% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
First reportedQ4 2014
Last reportedQ3 2024
Metric ID:
commercial_liabilities_otherHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $8.98B | $9.38B | $10.73B | $10.64B | $10.55B | $11.58B | $12.52B | $12.06B | $13.72B | $14.17B | $15.36B | $14.13B | $13.72B | $14.62B | $17.64B | $17.23B | $15.02B | $16.80B | $18.52B | $16.58B |
| QoQ Change | — | +4.4% | +14.4% | -0.9% | -0.9% | +9.9% | +8.1% | -3.7% | +13.7% | +3.3% | +8.4% | -8.0% | -2.9% | +6.6% | +20.7% | -2.3% | -12.8% | +11.8% | +10.3% | -10.5% |
| YoY Change | — | — | — | — | +17.4% | +23.5% | +16.7% | +13.4% | +30.1% | +22.3% | +22.6% | +17.1% | +0.0% | +3.2% | +14.9% | +22.0% | +9.5% | +14.9% | +5.0% | -3.8% |
Range$8.98B – $18.52B
CAGR+13.8%
Avg YoY Growth+14.3%
Median YoY Growth+15.8%
Other Commercial Liabilities at Other Companies
Frequently Asked Questions
- What is Amgen's other commercial liabilities?
- Amgen (AMGN) reported other commercial liabilities of $16.58B in Q1 2026.
- How has Amgen's other commercial liabilities changed year-over-year?
- Amgen's other commercial liabilities decreased by 3.8% year-over-year, from $17.23B to $16.58B.
- What is the long-term trend for Amgen's other commercial liabilities?
- Over 5 years (2020 to 2025), Amgen's other commercial liabilities has grown at a 12.8% compound annual growth rate (CAGR), from $10.14B to $18.52B.